Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Aysen Sekerim"'
Autor:
Greg G. Jones, Isabel Boned del Río, Sibel Sari, Aysen Sekerim, Lucy C. Young, Nicole Hartig, Itziar Areso Zubiaur, Mona A. El-Bahrawy, Rob E. Hynds, Winnie Lei, Miriam Molina-Arcas, Julian Downward, Pablo Rodriguez-Viciana
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant
Externí odkaz:
https://doaj.org/article/63c728d50eef448aa2fdb9117a059704
Autor:
Sibel Sari, Nicole Hartig, Aysen Sekerim, Julian Downward, Itziar Areso Zubiaur, Miriam Molina-Arcas, Winnie Lei, Greg G. Jones, Isabel Boned del Río, Lucy C. Young, Mona El-Bahrawy, Pablo Rodriguez-Viciana, Robert E. Hynds
Publikováno v:
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Nature communications, vol 10, iss 1
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Nature communications, vol 10, iss 1
Targeted inhibition of the ERK-MAPK pathway, upregulated in a majority of human cancers, has been hindered in the clinic by drug resistance and toxicity. The MRAS-SHOC2-PP1 (SHOC2 phosphatase) complex plays a key role in RAF-ERK pathway activation by
Autor:
Sibel Sari, Isabel Boned del Río, Julian Downward, Nicole Hartig, Mona El-Bahrawy, Aysen Sekerim, Pablo Rodriguez-Viciana, Miriam Molina-Arcas, Greg G. Jones, Lucy C. Young
Publikováno v:
Molecular Cancer Research. 18:B26-B26
Mutual exclusivity of RAS and BRAF mutations in multiple cancer types illustrates the key role of the RAF-MEK-ERK signaling pathway in mediating RAS oncogenesis. Although MEK inhibitors in particular are potent and specific, their on-target toxicity